Credit: KVK Tech
A Newtown Township-based pharmaceutical company has recently announced their drug, Lomaira, has been approved by the U.S. Food and Drug Administration (FDA) for weight reduction in obsese and overweight adults.
A recent press release notes Lomaira is the only strength of phentermine hydrochloride that can be taken up to three times a day before meals.
“At KVK Tech, we are committed to developing high-quality, FDA-approved medicines that address unmet medical needs, while ensuring affordable options for all appropriate patients,” said Anthony Tabasso, President and Chief Executive Officer of KVK Tech, located on Terry Drive in the township. “With Lomaira, we’re giving physicians and patients access to a low-cost, low-dose version of a weight-reduction medicine, phentermine, that has been prescribed by physicians for over 50 years.”
Appropriate patients for the drug include those that have a body mass index (BMI) of 30 or more or those with a BMI of 27 or more with at least one weight-related condition such as controlled high blood pressure, diabetes, or high cholesterol.
“Patients can take Lomaira up to three times a day, before meals – not just in the morning as with the higher dose formulations of phentermine,” said Tabasso. “We developed Lomaira with this dosing flexibility and affordability in mind.”
According to a press release introduced by the company earlier this week, phentermine hydrochloride, an appetite suppressant, is the most commonly prescribed drug for weight loss – with over 7 million prescriptions written for phentermine yearly by a wide range of healthcare professionals.
Lomaira is also expected to be reasonably priced; through KVK Tech’s Lomaira Lo-Cost Access Program, eligible patients will pay no more than 50¢ per tablet for the duration of treatment.
The drug is anticipated to become available by the end of September and will be exclusively manufactured and packaged in the United States, in the strictest accordance with FDA, DEA, and DEP guidelines.
